Evidence map›Paper›PMID 29170510›Full record

ArticleNature communications2017

Whole blood stabilization for the microfluidic isolation and molecular characterization of circulating tumor cells.

Keith H K Wong, Shannon N Tessier, David T Miyamoto, Kathleen L Miller, Lauren D Bookstaver, Thomas R Carey, Cleo J Stannard, Vishal Thapar, Eric C Tai, Kevin D Vo and 9 more

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Nature communications, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 40 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
40citing papers in PubMed, 1 pooled it
3.1field-weighted citation impact, top 8% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

40 citing papers in PubMed, 1 synthesis or guideline pooled it, 64 citations in OpenAlex.

  1. Pooled it
  2. Article
  3. Review
  4. Review
  5. Review
  6. Article
  7. Review
  8. Review
  9. Review
  10. Review
  11. Article
  12. Article
  13. Article
  14. Article
  15. Review
  16. Review
  17. Article
  18. Article
  19. ViaChip for Size-based Enrichment of Viable Cells.Sensors and actuators. B, Chemical · 2022
    Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

19 authors at 2 institutions in 1 country.

Keith H K WongBioMEMS Resource Center, Center for Engineering in Medicine, Massachusetts General Hospital, Harvard Medical School, Boston, MA, 02114, USA.ORCID http://orcid.org/0000-0002-6578-0373
Shannon N TessierBioMEMS Resource Center, Center for Engineering in Medicine, Massachusetts General Hospital, Harvard Medical School, Boston, MA, 02114, USA.
David T MiyamotoCancer Center, Massachusetts General Hospital, Harvard Medical School, Boston, MA, 02114, USA.
Kathleen L MillerBioMEMS Resource Center, Center for Engineering in Medicine, Massachusetts General Hospital, Harvard Medical School, Boston, MA, 02114, USA.
Lauren D BookstaverBioMEMS Resource Center, Center for Engineering in Medicine, Massachusetts General Hospital, Harvard Medical School, Boston, MA, 02114, USA.
Thomas R CareyBioMEMS Resource Center, Center for Engineering in Medicine, Massachusetts General Hospital, Harvard Medical School, Boston, MA, 02114, USA.
Cleo J StannardBioMEMS Resource Center, Center for Engineering in Medicine, Massachusetts General Hospital, Harvard Medical School, Boston, MA, 02114, USA.
Vishal ThaparCancer Center, Massachusetts General Hospital, Harvard Medical School, Boston, MA, 02114, USA.
Eric C TaiCancer Center, Massachusetts General Hospital, Harvard Medical School, Boston, MA, 02114, USA.
Kevin D VoCancer Center, Massachusetts General Hospital, Harvard Medical School, Boston, MA, 02114, USA.
Erin S EmmonsCancer Center, Massachusetts General Hospital, Harvard Medical School, Boston, MA, 02114, USA.
Haley M PleskowDepartment of Radiation Oncology, Massachusetts General Hospital, Harvard Medical School, Boston, MA, 02114, USA.
Rebecca D SandlinBioMEMS Resource Center, Center for Engineering in Medicine, Massachusetts General Hospital, Harvard Medical School, Boston, MA, 02114, USA.
Lecia V SequistCancer Center, Massachusetts General Hospital, Harvard Medical School, Boston, MA, 02114, USA.
David T TingCancer Center, Massachusetts General Hospital, Harvard Medical School, Boston, MA, 02114, USA.
Daniel A HaberCancer Center, Massachusetts General Hospital, Harvard Medical School, Boston, MA, 02114, USA.
Shyamala MaheswaranDepartment of Surgery, Massachusetts General Hospital, Harvard Medical School, Boston, MA, 02114, USA.
Shannon L StottBioMEMS Resource Center, Center for Engineering in Medicine, Massachusetts General Hospital, Harvard Medical School, Boston, MA, 02114, USA. sstott@mgh.harvard.edu.
Mehmet TonerBioMEMS Resource Center, Center for Engineering in Medicine, Massachusetts General Hospital, Harvard Medical School, Boston, MA, 02114, USA. mtoner@hms.harvard.edu.
Harvard University · USHoward Hughes Medical Institute · US

Funding

Point-of care Microfluidics for Early Detection of CancerU01EB012493 · NIBIB · MASSACHUSETTS GENERAL HOSPITAL · PI HABER, DANIEL A., TONER, MEHMET · 2010 to 2018
$19.6M
Bio-MicroElectroMechanical Systems Resource CenterP41EB002503 · NIBIB · MASSACHUSETTS GENERAL HOSPITAL · PI TONER, MEHMET · 2004 to 2018
$17.4M
Interdepartmental Neuroscience CenterP30NS045776 · NINDS · MASSACHUSETTS GENERAL HOSPITAL · PI BREAKEFIELD, XANDRA OWENS, TANNOUS, BAKHOS A · 2003 to 2018
$11.1M
Howard Hughes Medical InstituteNIBIB NIH HHS P41 EB002503NIBIB NIH HHS U01 EB012493NINDS NIH HHS P30 NS045776
6 · The paper itself

Abstract

Precise rare-cell technologies require the blood to be processed immediately or be stabilized with fixatives. Such restrictions limit the translation of circulating tumor cell (CTC)-based liquid biopsy assays that provide accurate molecular data in guiding clinical decisions. Here we describe a method to preserve whole blood in its minimally altered state by combining hypothermic preservation with targeted strategies that counter cooling-induced platelet activation. Using this method, whole blood preserved for up to 72 h can be readily processed for microfluidic sorting without compromising CTC yield and viability. The tumor cells retain high-quality intact RNA suitable for single-cell RT-qPCR as well as RNA-Seq, enabling the reliable detection of cancer-specific transcripts including the androgen-receptor splice variant 7 in a cohort of prostate cancer patients with an overall concordance of 92% between fresh and preserved blood. This work will serve as a springboard for the dissemination of diverse blood-based diagnostics.

Indexed as

Biomarkers, TumorBlood PreservationCase-Control StudiesCell Line, TumorCell SeparationGene Expression ProfilingHumansMaleMicrofluidicsNeoplastic Cells, CirculatingPlatelet ActivationProstatic NeoplasmsProtein IsoformsReceptors, AndrogenReverse Transcriptase Polymerase Chain ReactionRNA, NeoplasmAR protein, humanBiomarkers, TumorProtein IsoformsReceptors, AndrogenRNA, Neoplasm

Identifiers

PMID29170510
PMCPMC5700979
OpenAlexW2769965575

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.